TG Therapeutics Inc (TGTX) - Financial and Strategic SWOT Analysis Review

Date: May 9, 2019
Pages: 50
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: T0FF5B77BCCEN
Leaflet:

Download PDF Leaflet

TG Therapeutics Inc (TGTX) - Financial and Strategic SWOT Analysis Review
TG Therapeutics Inc (TGTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases. The company develops two therapies, namely, TG-1101 (ublituximab) and TGR-1202 for the treatment of hematological malignancies. TG-1101 glycoengineered monoclonal antibody that targets a unique epitope on the B-lymphocyte CD20 antigen and TG-1202 is an orally available PI3K delta inhibitor. Its other product candidates include inhibitors of IRAK4 and anti-PD-L1 and anti-GITR antibodies. The company also offers products and technologies for in-licensing, partnership, acquisition and investment. TG Therapeutics is headquartered in New York City, New York, the US.

TG Therapeutics Inc Key Recent Developments

Mar 08,2019 TG Therapeutics moves forward with MZL therapy umbralisib
Feb 28,2019 TG Therapeutics Announces Positive Outcome from Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with RelapsedRefractory Marginal Zone Lymphoma
Nov 30,2018 TG Therapeutics, Inc. Recaps Triple Therapy Data Presentations at the Upcoming 60th American Society of Hematology Annual Meeting and Exposition

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY

TG Therapeutics Inc - Key Facts
TG Therapeutics Inc - Key Employees
TG Therapeutics Inc - Key Employee Biographies
TG Therapeutics Inc - Major Products and Services
TG Therapeutics Inc - History
TG Therapeutics Inc - Company Statement
TG Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
TG Therapeutics Inc - Business Description
TG Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
TG Therapeutics Inc - Strengths
TG Therapeutics Inc - Weaknesses
TG Therapeutics Inc - Opportunities
TG Therapeutics Inc - Threats
TG Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
TG Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 08, 2019: TG Therapeutics moves forward with MZL therapy umbralisib
Feb 28, 2019: TG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Feb 28, 2019: TG Therapeutics Announces Positive Outcome from Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with RelapsedRefractory Marginal Zone Lymphoma
Nov 30, 2018: TG Therapeutics, Inc. Recaps Triple Therapy Data Presentations at the Upcoming 60th American Society of Hematology Annual Meeting and Exposition
Nov 09, 2018: TG Therapeutics provides business update and reports third quarter 2018 financial results
Oct 11, 2018: TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the 34th Congress of ECTRIMS
Oct 08, 2018: TG Therapeutics, Inc. Highlights Schedule of Events at the Upcoming 34th Congress of ECTRIMS
Sep 26, 2018: TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Accepted for Oral Presentation at the Upcoming 34th Congress of ECTRIMS
Aug 07, 2018: TG Therapeutics provides business update and reports second quarter 2018 financial results
Jun 04, 2018: TG Therapeutics Names Adam Waldman As Chief Commercial Officer

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

TG Therapeutics Inc, Key Facts
TG Therapeutics Inc, Key Employees
TG Therapeutics Inc, Key Employee Biographies
TG Therapeutics Inc, Major Products and Services
TG Therapeutics Inc, History
TG Therapeutics Inc, Subsidiaries
TG Therapeutics Inc, Key Competitors
TG Therapeutics Inc, Ratios based on current share price
TG Therapeutics Inc, Annual Ratios
TG Therapeutics Inc, Annual Ratios (Cont...1)
TG Therapeutics Inc, Interim Ratios
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
TG Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

TG Therapeutics Inc, Performance Chart (2014 - 2018)
TG Therapeutics Inc, Ratio Charts
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Infinity Pharmaceuticals Inc
Hoffmann-La Roche Inc
Dr. Reddy’s Laboratories Limited
Cyclacel Pharmaceuticals Inc
Skip to top


Ask Your Question

TG Therapeutics Inc (TGTX) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: